DK2804587T3 - Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed - Google Patents

Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed Download PDF

Info

Publication number
DK2804587T3
DK2804587T3 DK13703152.2T DK13703152T DK2804587T3 DK 2804587 T3 DK2804587 T3 DK 2804587T3 DK 13703152 T DK13703152 T DK 13703152T DK 2804587 T3 DK2804587 T3 DK 2804587T3
Authority
DK
Denmark
Prior art keywords
biodeless
pharmaceuticals
formulation
procedure
increasing
Prior art date
Application number
DK13703152.2T
Other languages
English (en)
Inventor
Amnon Hoffman
Anna Elgart
Irina Cherniakov
Abraham J Domb
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Application granted granted Critical
Publication of DK2804587T3 publication Critical patent/DK2804587T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK13703152.2T 2012-01-19 2013-01-17 Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed DK2804587T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261588341P 2012-01-19 2012-01-19
US201261615457P 2012-03-26 2012-03-26
US201261696540P 2012-09-04 2012-09-04
US201261704893P 2012-09-24 2012-09-24
PCT/IL2013/050047 WO2013108254A1 (en) 2012-01-19 2013-01-17 Formulation and method for increasing oral bioavailability of drugs

Publications (1)

Publication Number Publication Date
DK2804587T3 true DK2804587T3 (da) 2019-08-12

Family

ID=47678957

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13703152.2T DK2804587T3 (da) 2012-01-19 2013-01-17 Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed

Country Status (5)

Country Link
US (3) US20140348926A1 (da)
EP (1) EP2804587B1 (da)
DK (1) DK2804587T3 (da)
ES (1) ES2739194T3 (da)
WO (1) WO2013108254A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013172999A1 (en) 2012-05-16 2013-11-21 Mewa Singh Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
PL3057604T3 (pl) 2013-10-14 2021-12-20 Nanosphere Health Sciences Inc. Kompozycje nanocząstek i sposoby jako nośniki czynników nutraceutycznych przez błony komórkowe i bariery biologiczne
WO2015118549A1 (en) * 2014-02-10 2015-08-13 F&C Licorice Ltd. Encapsulated biologically active agents
US10213391B2 (en) 2014-05-06 2019-02-26 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
US10117891B2 (en) 2014-09-16 2018-11-06 India Globalization Capital, Inc. Cannabinoid composition for treating pain
CA2970651C (en) * 2014-12-12 2020-09-29 Ojai Energetics Pbc Microencapsulated cannabinoid compositions
US10350165B2 (en) 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
US11707436B2 (en) 2014-12-15 2023-07-25 Nanosphere Health Sciences Inc. Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of NSAIDS
US10751300B2 (en) 2015-01-25 2020-08-25 India Globalization Capital, Inc. Composition and method for treating seizure disorders
WO2016144376A1 (en) 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
DK3381451T3 (da) * 2015-08-28 2025-10-06 Caliway Biopharmaceuticals Co Ltd Farmaceutisk sammensætning brugt til at reducere lokaliseret fedt samt brug af den farmaceutiske sammensætning
DK3368014T3 (da) 2015-10-26 2024-01-08 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Nye formuleringer af cannabinoider
WO2017074266A1 (en) * 2015-10-30 2017-05-04 National University Of Singapore Androgen biosynthesis inhibitor
EP3251668A1 (en) 2016-06-02 2017-12-06 Pharmotech SA Cannabidiol compositions and uses thereof
EP3471746A4 (en) 2016-06-15 2020-02-26 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR TREATING CRAMPING SEASONS
EP3290026A1 (en) 2016-09-06 2018-03-07 Athenion AG Method for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
IL248149B (en) 2016-09-29 2020-03-31 Garti Nissim Dilutable formulations of cannbinoids and processes for their preparation
IL248150B (en) 2016-09-29 2018-05-31 Garti Nissim Method for selective extraction of cannabinoids from a plant source
CA3077624A1 (en) * 2016-10-01 2018-04-05 James Smeeding Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
ES2979135T3 (es) * 2016-10-14 2024-09-24 Cipla Ltd Composiciones farmacéuticas que comprenden rifaximina
US20180169061A1 (en) * 2016-12-15 2018-06-21 Ascent Pharmaceuticals, Inc. Non-aqueous delta9-tetrahydrocannabinol oral liquid formulations
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
US11261215B2 (en) 2017-09-19 2022-03-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Somatostatin prodrugs
EP3511325A1 (en) 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
EP3536332A1 (en) 2018-03-07 2019-09-11 Athenion AG Krill oil for solubilizing poorly water-soluble dietary supplements and pharmaceutically active agents
IL261132A (en) 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
WO2020123407A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN111632052A (zh) * 2019-03-01 2020-09-08 沈阳药科大学 胡椒碱在制备sEH抑制剂中的应用
US20200375911A1 (en) * 2019-06-03 2020-12-03 Fresh Cut Development, Llc Cannabidiol nanocrystal compositions
EP4025067A4 (en) * 2019-09-06 2023-09-13 Quicksilver Scientific, Inc. MICRO-EMULSION DELIVERY SYSTEMS FOR WATER-BASED BEVERAGES
US12653782B2 (en) 2019-09-12 2026-06-16 Nulixir Inc. Controlled release concentrate and suspensions including the same
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス,インコーポレイテッド カンナビジオールの経皮送達
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
US11872197B2 (en) 2020-03-03 2024-01-16 Another Chance Nutra, LLC Method of treatment or alleviating symptoms of a disorder with curcumin
WO2021178871A1 (en) 2020-03-05 2021-09-10 University Of Miami Cannabidiol nanodrug formulations and methods for use the same
EP3919046A1 (en) 2020-06-02 2021-12-08 Athenion AG Method for solubilizing natural, endogenous and synthetic cannabinoids
AU2021307693A1 (en) * 2020-07-15 2023-02-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Oral cavity polymeric delivery systems
EP4057993A2 (en) 2020-07-29 2022-09-21 Karnak Technologies, LLC Oral compositions of lipophilic diety supplements, nutraceuticals and beneficial edible oils
AU2021317263B2 (en) 2020-07-29 2024-08-01 Karnak Technologies, Llc Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives
WO2022211481A1 (ko) 2021-04-01 2022-10-06 에스엔제이 파마 인크 생활성물질의 경구용 나노입자 및 이의 제조방법
US20220347119A1 (en) * 2021-04-30 2022-11-03 Reshma N. Kheraj Medicated drink
EP4396162A4 (en) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc ASYMMETRIC ALLYL TRYPTAMINES
WO2023043852A1 (en) * 2021-09-14 2023-03-23 Nulixir Inc. Stable non-aqueous compositions of functional ingredients and methods of making the same
US12465578B2 (en) 2021-09-25 2025-11-11 Alexander Shulgin Research Institute, Inc. Substituted alpha-ethyl phenylalkylamines
EP4186497A1 (en) 2021-11-26 2023-05-31 Dorian Bevec Alpha lipoic acid, epigallocatechin 3-gallate, and curcumin as a medicament for the treatment of arthritis or sars-cov-2 infection
LU501323B1 (en) 2022-01-25 2023-07-25 Kemijski Inst Cannabinoid complexes with improved properties
IT202200025767A1 (it) 2022-12-15 2024-06-15 Prolabin & Tefarm S R L Formulazione comprendente polifenoli vanilloidi supportati su solidi lamellari per ridurre i livelli plasmatici di CGRP e sue applicazioni.
CN119424347A (zh) * 2024-11-19 2025-02-14 通威农业发展有限公司 柚皮素纳米粒在头孢噻呋长效制剂制备中的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816247A (en) * 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
EP0650728B1 (en) 1993-10-29 2002-02-27 Council of Scientific and Industrial Research Pharmaceutical compositions containing piperine and an antituberculosis or antileprosydrug
IN176897B (da) 1993-10-29 1996-09-28 Cadila Lab Ltd
US5536506A (en) 1995-02-24 1996-07-16 Sabinsa Corporation Use of piperine to increase the bioavailability of nutritional compounds
US5744161A (en) 1995-02-24 1998-04-28 Sabinsa Corporation Use of piperine as a bioavailability enhancer
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
AU2002366588A1 (en) 2001-12-13 2003-06-23 Council Of Scientific And Industrial Research Bioavailability enhancing activity of zingiber officinale linn and its extracts/fractions thereof
US20060148727A1 (en) * 2004-12-01 2006-07-06 Curt Hendrix Folate based composition for neurological and cognitive applications
PT1903866E (pt) * 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
US9192644B2 (en) * 2006-03-06 2015-11-24 The Regents Of The University Of California Bioavailable curcuminoid formulations for treating Alzheimer's disease and other age-related disorders
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
GB0623838D0 (en) 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2008095122A2 (en) 2007-01-31 2008-08-07 Bioactives, Inc. Methods of reducing 15-f2t-isop levels in mammals
US8101274B2 (en) 2007-06-11 2012-01-24 Spedden Richard H Solid state membranes with surface-embedded glycosylated amphiphilic molecules and micelles formed therefrom
US8859001B2 (en) 2007-10-18 2014-10-14 Mia Levite Fenoldopam formulations and pro-drug derivatives
WO2010010431A1 (en) * 2008-07-24 2010-01-28 National Institute Of Pharmaceutical Education And Research Self-nano-emulsifying curcuminoids composition with enhanced bioavailability
US20100041622A1 (en) * 2008-08-13 2010-02-18 Bromley Philip J Compositions containing aminoalkanes and aminoalkane derivatives
IT1395086B1 (it) 2009-03-11 2012-09-05 Velleja Res Srl Composizioni comprendenti curcumina in forma complessata con fosfolipidi e piperina ad azione chemio-sensibilizzante
PL2629610T3 (pl) 2010-07-27 2018-02-28 Flex Pharma, Inc. Sposoby i kompozycje do zapobiegania i zmniejszania kurczy mięśni i do regeneracji po nerwowo-mięśniowym podrażnieniu i zmęczeniu po ćwiczeniach fizycznych
EP2637655B1 (en) * 2010-11-08 2019-01-09 Cadila Pharmaceuticals Ltd. Pharmaceutical composition of taxoids
US11351139B2 (en) * 2013-02-28 2022-06-07 Basf As Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same

Also Published As

Publication number Publication date
EP2804587B1 (en) 2019-05-08
EP2804587A1 (en) 2014-11-26
US20140348926A1 (en) 2014-11-27
US20200009067A1 (en) 2020-01-09
WO2013108254A1 (en) 2013-07-25
US12161763B2 (en) 2024-12-10
ES2739194T3 (es) 2020-01-29
US20240335391A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
DK3238709T3 (da) Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
DK2917763T3 (da) Lidar-målesystem og lidar-målefremgangsmåde
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2903600T3 (da) Virusholdig formulering og anvendelse deraf
DK2800565T3 (da) Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK3608325T3 (da) Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
EP2930714A4 (en) SINGLE SYNTHETIZATION SYSTEM AND SINGLE SYNTHETIZATION PROCEDURE
DK2854883T3 (da) Biomatrix-hydrogeler og fremgangsmåder til anvendelse deraf
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
DK2838533T3 (da) Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
DK2892912T3 (da) C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
DK2919923T3 (da) Holder-sortiment og rengøringsapparater til rengøring af åndedrætsapparater
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
DK3080281T3 (da) System til administration af mikrobiske inokulanter og relaterede materialer og fremgangsmåder
DK3050883T3 (da) Fremgangsmåde til fremstilling af diazabicyclooctanderivater og mellemprodukter
DK2867422T3 (da) Anordning til armering af sammenføjninger og søjler i kombination
DK3049059T3 (da) Intranasal dhe formulering til behandlingen af hovedpine
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
DK2922860T3 (da) Hydrerede og vandfri polymorfer af 2&#39;-o-fucosyllactose samt fremgangsmåder til fremstilling deraf
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner